P
Paul S. Lietman
Researcher at Johns Hopkins University School of Medicine
Publications - 166
Citations - 10969
Paul S. Lietman is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Pharmacokinetics & Tobramycin. The author has an hindex of 54, co-authored 166 publications receiving 10722 citations. Previous affiliations of Paul S. Lietman include University of California, San Diego & Research Triangle Park.
Papers
More filters
Journal ArticleDOI
Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration
TL;DR: It is demonstrated that a high peak concentration relative to the MIC for the infecting organism is a major determinant of the clinical response to aminoglycoside therapy.
Journal ArticleDOI
Acyclovir Prophylaxis of Herpes-Simplex-Virus Infections
TL;DR: Although acyclovir does no appear to eradicate latent infection, it can provide effective prophylaxis against reactivated infections and appears to be a potent inhibitor of HSV replication.
Journal ArticleDOI
Double-Blind Comparison of the Nephrotoxicity and Auditory Toxicity of Gentamicin and Tobramycin
Craig R. Smith,J. J. Lipsky,Oscar L. Laskin,D B Hellmann,E D Mellits,J. Longstreth,Paul S. Lietman +6 more
TL;DR: It is concluded that tobramycin causes nephrotoxicity less frequently than does gentamicin.
Journal ArticleDOI
Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia
TL;DR: The potential importance of achieving adequate aminoglycoside levels in patients with gram-negative pneumonia is suggested, as achieving an adequate peak concentration was the most important discriminating factor by multivariate analysis.
Journal ArticleDOI
The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.
TL;DR: The results suggest the importance of achieving adequate early aminoglycoside levels in patients with gram-negative bacteremia and show that therapeutic early peak concentration was a significant factor in the presence of three other factors: severity of underlying illness, peak temperature, and initial leukocyte count.